Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead.
Gilles Nevez, Solène Le Gal
https://pubmed.ncbi.nlm.nih.gov/31548210/Actively Recruiting
Led by University Hospital, Tours · Updated on 2026-10-09
100
Participants Needed
3
Research Sites
104 weeks
Total Duration
Researchers are evaluating the effectiveness of daily caspofungin aerosols compared to placebo, alongside standard systemic antifungal therapy, for treating Pneumocystis pneumonia. This trial aims to support a decision about moving forward to a larger phase III trial. Pneumocystis jirovecii causes severe pneumonia especially in immunocompromised patients, with high rates of hospitalization, mechanical ventilation, and mortality. Current treatments have limitations and side effects, so new delivery methods like aerosolized caspofungin are being explored. The study includes two parts an initial open-label dose escalation phase to determine the best nebulized caspofungin regimen, followed by a randomized, blinded, placebo-controlled phase comparing daily caspofungin aerosol or placebo aerosols alongside conventional systemic antifungal treatments. Caspofungin aerosols are delivered via a vibrating mesh nebulizer once daily for up to seven days. Placebo aerosols contain saline and are administered similarly. The trial uses conventional systemic antifungal drugs such as co-trimoxazole or second-line salvage therapies in all groups. Participants will be closely monitored during treatment for safety and effectiveness, with assessments including clinical outcomes at day 7, fungal clearance, lung infection markers, pharmacokinetics of nebulized caspofungin, mortality up to day 90, and morbidity. Safety is assessed daily during inhalation therapy. The trial duration includes up to seven days of aerosol treatment with follow-up visits extending to day 90 to evaluate longer-term outcomes and adverse events.
CONDITIONS
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
G
Guillaume DESOUBEAUX, Prof
S
Stephan EHRMANN, Prof
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Tours
Lead Sponsor
University Hospital, Angers
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants receive ascending doses of nebulized caspofungin to evaluate safety and determine the best dosing regimen over one week. They are closely monitored in intensive care during this phase.
Daily monitoring visits
Duration - Up to 7 days
Participants are randomly assigned to receive daily nebulized caspofungin aerosols or placebo aerosols alongside conventional systemic antifungal therapy for up to seven days.
Daily treatment visits
Duration - Up to 90 days
Participants are monitored for clinical outcomes, safety, fungal clearance, and lung infection markers up to 90 days after treatment begins.
Scheduled follow-up visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Gilles Nevez, Solène Le Gal
https://pubmed.ncbi.nlm.nih.gov/31548210/Stephan Ehrmann, Emmanuelle Mercier, Laurent Vecellio...
https://pubmed.ncbi.nlm.nih.gov/18046534/Jeremy R Beitler, Todd Sarge, Valerie M Banner-Goodspeed...
https://pubmed.ncbi.nlm.nih.gov/30776290/Guillaume Desoubeaux, Adrien Lemaignen, Stephan Ehrmann
https://pubmed.ncbi.nlm.nih.gov/32194238/Annie Wong-Beringer, Maria Polikandritou Lambros, Paul M Beringer...
https://pubmed.ncbi.nlm.nih.gov/16304338/Maria Luísa Lobo, Francisco Esteves, Bruno de Sousa...
https://pubmed.ncbi.nlm.nih.gov/23940606/Guillaume Desoubeaux, Manon Dominique, Florent Morio...
https://pubmed.ncbi.nlm.nih.gov/26935726/A H Limper
https://pubmed.ncbi.nlm.nih.gov/9872631/Maddalena Peghin, Jay A Fishman, Paolo Antonio Grossi
https://pubmed.ncbi.nlm.nih.gov/41151592/J A McKinnell, A P Cannella, D F Kunz...
https://pubmed.ncbi.nlm.nih.gov/22548840/University Hospital, Tours
Lead Sponsor
University Hospital, Angers
Collaborating Sponsor